<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859482</url>
  </required_header>
  <id_info>
    <org_study_id>Ntz-Tregs1</org_study_id>
    <nct_id>NCT00859482</nct_id>
  </id_info>
  <brief_title>Differential Immune Effects of Natalizumab</brief_title>
  <official_title>A Phase IV Study to Investigate Differential Immune Effects of Natalizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene
      4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade
      of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also
      with central nervous system (CNS) immune surveillance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency
      of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+
      regulatory T cells (Tregs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Function of T regulatory cells</measure>
    <time_frame>at month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in distinct immune cell lines</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Multiple Sclerosis, Relapsing Remitting</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      full blodd
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients initiating natalizumab for treatment of relapsing remitting MS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapsing remitting MS

          -  indication for natalizumab treatment

        Exclusion Criteria:

          -  other disease modifying agents within 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Putzki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KSSG, 9007 St. Gallen, Switzerland</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Norman Putzki, MD</name_title>
    <organization>Cantonal Hospital St. Gallen</organization>
  </responsible_party>
  <keyword>natalizumab</keyword>
  <keyword>multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

